MBX Biosciences (MBX) Stock Price, News & Analysis

Company Overview

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide therapies for endocrine and metabolic disorders. The company uses its Precision Plus peptide engineering platform to design medicines intended to provide targeted biological activity, longer duration and more convenient dosing than conventional peptide treatments.

MBX Biosciences’ lead program is MBX 2109, an investigational long-acting parathyroid hormone replacement therapy being developed for people with hypoparathyroidism, a disorder in which the body produces insufficient parathyroid hormone and has difficulty maintaining normal calcium levels. The company’s pipeline also includes additional preclinical and clinical-stage peptide programs addressing other endocrine diseases.

Founded in 2019 and headquartered in Indianapolis, Indiana, MBX Biosciences conducts its research and clinical development activities primarily in the United States while advancing therapies intended for patients in broader international markets. Its common stock trades on the Nasdaq under the symbol MBX.

Key Stats

• Today's Range: $52.29 to $56.57
• 50-Day Range: $48.50 to $68.62
• 52-Week Range: $20.21 to $72.64
• Volume: 667,264 shs
• Average Volume: 583,884 shs
• Market Capitalization: $2.69 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $87.00
• Consensus Rating: Moderate Buy

MBX Biosciences Stock Analysis - MarketRank™

MBX Biosciences scored higher than 66% of companies evaluated by MarketBeat, and ranked 362nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MBX Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 10 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

MBX Biosciences has a consensus price target of $87.00, representing about 55.7% upside from its current price of $55.87.

Amount of Analyst Coverage

MBX Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MBX Biosciences are expected to decrease in the coming year, from ($3.10) to ($4.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MBX Biosciences is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MBX Biosciences is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MBX Biosciences has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.33% of the float of MBX Biosciences has been sold short.

Short Interest Ratio / Days to Cover

MBX Biosciences has a short interest ratio ("days to cover") of 7.46.

Change versus previous month

Short interest in MBX Biosciences has recently decreased by 0.97%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MBX Biosciences does not currently pay a dividend.

Dividend Growth

MBX Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.79

News Sentiment

MBX Biosciences has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for MBX Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for MBX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

3 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MBX Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,335.00 in company stock.

Percentage Held by Insiders

31.09% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

MBX Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/01/2026
• Jefferies Global Healthcare Conference: 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MBX
• Previous Symbol: NASDAQ:MBX
• CIK: 1776111
• Web: mbxbio.com
• Phone: (317) 989-3100
• Fax: N/A
• Employees: 63
• Year Founded: 2018

Price Target and Rating

• Average Price Target for MBX Biosciences: $87.00
• High Price Target: $150.00
• Low Price Target: $18.00
• Potential Upside/Downside: +55.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.02%
• Return on Assets: -24.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.08
• Quick Ratio: 18.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.22 per share
• Price / Book: 6.80

Miscellaneous

• Outstanding Shares: 48,160,000
• Free Float: 33,187,000
• Market Cap: $2.69 billion
• Optionable: Optionable
• Beta: 0.10